Securian Asset Management Inc increased its position in shares of LivaNova PLC (NASDAQ:LIVN) by 9.4% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 5,950 shares of the company’s stock after acquiring an additional 510 shares during the period. Securian Asset Management Inc’s holdings in LivaNova were worth $738,000 as of its most recent filing with the Securities and Exchange Commission.
Other institutional investors have also recently bought and sold shares of the company. Creative Planning purchased a new stake in LivaNova during the 3rd quarter valued at about $248,000. Retirement Systems of Alabama grew its position in LivaNova by 11.2% during the 3rd quarter. Retirement Systems of Alabama now owns 62,747 shares of the company’s stock valued at $7,779,000 after purchasing an additional 6,300 shares during the last quarter. Fisher Asset Management LLC grew its position in LivaNova by 50.5% during the 3rd quarter. Fisher Asset Management LLC now owns 245,378 shares of the company’s stock valued at $30,420,000 after purchasing an additional 82,378 shares during the last quarter. First Quadrant L P CA grew its position in LivaNova by 62.4% during the 3rd quarter. First Quadrant L P CA now owns 150,722 shares of the company’s stock valued at $18,685,000 after purchasing an additional 57,931 shares during the last quarter. Finally, Texas Permanent School Fund grew its position in LivaNova by 8.7% during the 3rd quarter. Texas Permanent School Fund now owns 30,574 shares of the company’s stock valued at $3,790,000 after purchasing an additional 2,440 shares during the last quarter. 87.18% of the stock is currently owned by institutional investors and hedge funds.
Shares of NASDAQ LIVN opened at $108.34 on Wednesday. The company has a current ratio of 1.51, a quick ratio of 1.08 and a debt-to-equity ratio of 0.03. The stock has a market cap of $5.56 billion, a PE ratio of 32.73, a P/E/G ratio of 3.26 and a beta of 0.95. LivaNova PLC has a 52-week low of $72.30 and a 52-week high of $131.54.
Several brokerages recently commented on LIVN. Stifel Nicolaus reissued a “buy” rating and set a $135.00 price objective on shares of LivaNova in a research report on Thursday, August 2nd. Needham & Company LLC reaffirmed a “buy” rating and set a $135.00 price target (up previously from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. BidaskClub raised shares of LivaNova from a “buy” rating to a “strong-buy” rating in a report on Thursday, July 26th. Zacks Investment Research raised shares of LivaNova from a “sell” rating to a “hold” rating in a report on Wednesday, July 4th. Finally, Jefferies Financial Group raised their price target on shares of LivaNova to $150.00 and gave the company a “buy” rating in a report on Tuesday, October 2nd. Three analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $113.33.
In related news, Director Daniel Jeffrey Moore sold 1,000 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The shares were sold at an average price of $121.58, for a total value of $121,580.00. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Douglas John Manko sold 2,058 shares of the firm’s stock in a transaction that occurred on Wednesday, August 15th. The stock was sold at an average price of $121.61, for a total transaction of $250,273.38. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 8,058 shares of company stock worth $963,033. Insiders own 0.41% of the company’s stock.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.
Further Reading: Asset Allocation
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.